Novavax Inc reports results for the quarter ended March 31 - Earnings Summary

• Novavax Inc NVAX.OQ reported quarterly adjusted earnings of $2.93​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.05. The mean expectation of five analysts for the quarter was for earnings of 71 cents per share. Wall Street expected results to range from -58 cents to $2.67 per share.

• Revenue rose 610.3% to $666.66 million from a year ago; analysts expected $343.85 million.

• Novavax Inc's reported EPS for the quarter was $2.93​.

• The company reported quarterly net income of $518.65 million.

• Novavax Inc shares had fallen by 7.2% this quarter and lost 26.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 244.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Novavax Inc is $18.50

This summary was machine generated from LSEG data May 8 at 02:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)